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A novel two-score system for 
interferon status segregates 
autoimmune diseases and 
correlates with clinical features
Y. M. El-Sherbiny1,4,5, A. Psarras1,5, M. Y. Md Yusof1,5, E. M. A. Hensor1,5, R. Tooze  2, G. Doody  2,  
A. A. A Mohamed1,3,5, D. McGonagle1,5, M. Wittmann1,5, P. Emery1,5 & E. M. Vital  1,5
Measurement of type I interferon (IFN-I) has potential to diagnose and stratify autoimmune diseases, 
but existing results have been inconsistent. Interferon-stimulated-gene (ISG) based methods may be 
affected by the modularity of the ISG transcriptome, cell-specific expression, response to IFN-subtypes 
and bimodality of expression. We developed and clinically validated a 2-score system (IFN-Score-A and 
-B) using Factor Analysis of 31 ISGs measured by TaqMan selected from 3-IFN-annotated modules. We 
evaluated these scores using in-vitro IFN stimulation as well as in sorted cells then clinically validated 
in a cohort of 328 autoimmune disease patients and healthy controls. ISGs varied in response to IFN-
subtypes and both scores varied between cell subsets. IFN-Score-A differentiated Systemic Lupus 
Erythematosus (SLE) from both Rheumatoid Arthritis (RA) and Healthy Controls (HC) (both p < 0.001), 
while IFN-Score-B differentiated SLE and RA from HC (both p < 0.001). In SLE, both scores were 
associated with cutaneous and hematological (all p < 0.05) but not musculoskeletal disease activity. 
Comparing with bimodal (IFN-high/low) classification, significant differences in IFN-scores were found 
between diagnostic groups within the IFN-high group. Our continuous 2-score system is more clinically 
relevant than a simple bimodal classification of IFN status. This system should allow improvement in 
diagnosis, stratification, and therapy in IFN-mediated autoimmunity.
The type I interferon (IFN-I) family has a central role in antiviral immunity as well as the pathogenesis of several 
autoimmune diseases: most notably in systemic lupus erythematosus (SLE), but also implicated in rheumatoid 
arthritis (RA). Many of the strongest genetic susceptibility variants for SLE encode proteins in the innate immune 
response including molecules involved in endogenous immune stimuli intensification, production of IFN-I, and 
regulation of cellular response to IFN-I1,2. Blockade of IFN-α or the shared IFNAR receptor have both demon-
strated efficacy. In RA, IFN-I is found in the synovium and is a biomarker in pre-clinical disease3,4. IFN activity 
is variable within and between autoimmune diseases and may have value in diagnosis, stratifying subtypes of 
disease and selecting patients for interferon-targeted therapy. However, measurement of IFN-I status is complex 
and existing IFN-I biomarkers show poor or inconsistent correlations with disease activity5,6 as well as response 
to IFN-I-blocking therapy7–10.
Because direct measurement of serum IFN-I proteins is insensitive, IFN-I activity is usually measured indi-
rectly using expression of interferon-stimulated genes (ISGs) as either a “signature”, which usually refers to a cat-
egorical variable representing high or low expression of ISGs11, or a “score”, which usually refers to a continuous 
variable derived from level of expression of a set of selected ISGs12–14.
ISG-based assays have limitations. First, the group of genes identified as ISGs may not represent a single 
immune phenomenon. The interferon transcriptome is modular with sets of ISGs described that respond not only 
to IFN-I but also to IFN-II and -III15 as well as non-IFN pathways. Second, gene expression may vary between 
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circulating cell populations16,17, and so assays that use whole blood18–22 or unsorted PBMCs23–26 may show appar-
ent differences in level of ISG expression that are in fact due to changes in the size of cell populations; such 
changes are characteristic of autoimmune diseases27. Lastly, previous IFN scores were bimodal (high or low) but 
the relative merits of bimodal categorization or continuous analysis have not been compared.
Our objective was to develop and clinically validate continuous Interferon Stimulated Gene Expression (ISG) 
scores for evaluation of IFN-mediated diseases, accounting for modularity of the ISG transcriptome, cell-specific 
expression, response to IFN-subtypes and bimodality of expression.
Results
Interferon Gene Expression Scoring. We first performed Taqman analysis of 10 genes from each of three 
IFN-annotated modules previously described, followed by Factor Analysis (FA) to determine whether the gene 
expression values of multiple genes were driven by a smaller number of unobserved (latent) continuous variables. 
We included 49 HC (mean (SD) age at sample 31.7 (8.8); 65% female), 114 SLE (45.7 (14.5); 93%), 133 UCTD 
(47.7 (15.1); 86%) and 32 RA patients (52.2 (15.5); 72%) (total n = 328).
When the FA was performed in the 31 genes, KMO values confirmed the sample adequacy; overall KMO = 0.93 
(‘superb’28) and KMO values for each of the individual genes all exceeded the acceptable 0.5 limit28. Bartlett’s test of 
sphericity was highly significant [Χ2(465) = 11445.2, p < 0.001], indicating sufficiently large correlations between the 
genes to permit FA. However, The determinant of the correlation matrix was low (<0.00001) when all genes were 
included, indicating multicollinearity between expression values in the 31 genes. Repeating the factor analysis in a 
reduced set of 19 genes selected for low squared multiple correlation with the others increased the determinant to 
0.00002 but gave very similar results (data not shown) therefore we proceeded with the full gene set.
The parallel analysis indicated that up to 7 factors were present in the data (Fig. S1); however, a simpler 
solution with fewer cross-loaded items was obtained with 2 factors, which still explained 84% of the variance. 
Eigenvalues for each of the initial 31 factors and factor loadings (pattern and structure matrix) for each gene are 
presented in online supplementary Tables S3 and S4.
A two-factor solution explained 84% of the variance with limited cross loading. There was substantive corre-
lation between the factors in the rotated solution (r = 0.56), supporting the use of oblique rotation which permits 
factors to be correlated. Eigenvalues for each of the initial 31 factors and factor loadings (pattern and structure 
matrix) for each gene are presented in supplementary Tables S3 and S4. ISG15 loaded most strongly onto Factor 
1; TAP1 loaded most strongly onto Factor 2; CASP1 did not substantively load onto either factor. Having excluded 
CASP1, IFI6, HERC5, EIF2AK2 & MX1 were cross-loaded. Table 1 shows the genes that contributed to each 
factor; we called these IFN Score A and IFN Score B. The relationship between IFN-Score A and B elements and 
biological functions obtained from GO; Geneontology and KEGG; Kyoto Encyclopedia of Genes and Genomes 
Databases is shown in supplementary Figs S2, S3 and S4 and Tables S7, S8 and S9.
Gene expression scores differ between cell subsets. We sorted cells to compare the contribution of 
each immune cell subset to these Scores. PBMCs from 10 SLE patients and 8 HC were sorted into CD14+ mono-
cytes, CD3+ T cells and CD56+CD3− NK cells, CD19+CD27−CD38− naïve B cells, CD19+CD27+CD38− memory 
B cells, and CD19+CD27+CD38+ plasmablasts. Overall levels of expression are shown in Fig. 1 and full data with 
statistical tests are shown in Table S5.
In SLE patients, expression of IFN Score A was significantly higher in monocytes than in other cell sub-
sets. While scores were lower in HC, they again reflected higher expression in monocytes relative to other cell 
subtypes. We next compared SLE and healthy control for each subset (between-group ratio, Fig. 1, Table S5). 
Expression levels in SLE patients exceeded those in HC to varying degrees depending on the subset.
The SLE:HC ratio for each subset was compared with monocytes (Table S5). For IFN Score A, there was not a 
statistically significant difference between monocytes and most cell subsets, although the ratios were substantively 
different. (Χ2(5) = 2.0, P = 0.855). The trends differed somewhat for IFN Score B. In SLE patients, expression levels 
were higher in monocytes than in all other cell subsets, as was found for IFN Score A. The largest differences 
between SLE and HC were seen in monocytes (2.4-fold elevation in SLE). However, in the remaining subsets 
the between-group differences were considerably smaller. At the 10% level of significance, the between group 
difference was 43% (P = 0.023), 33% (P = 0.067) and 47% (P = 0.004) smaller for T cells, memory B cells and 
plasmablasts respectively compared to monocytes; at the 20% level of significance there was evidence suggestive 
of overall variation between cell subtypes in the SLE:HC IFN Score B expression ratio (Χ2(5) = 8.9, P = 0.114).
Interferon Stimulated Gene Expression following in-vitro stimulation. The influence of IFN-α 
(IFN-I) and IFN-γ (IFN-II) on B cells were compared by adding each to a B cell culture system as previously 
described29. Hierarchically clustered heat map representation of global gene expression profiles showed that many 
ISGs were responsive to both IFN-α and IFN-γ, while other ISGs responded specifically to IFN-α29. We analysed 
data for the 31 genes that we had selected for qPCR analysis in the present study. Fold change was measured at 
6 hours as this time point showed the greatest and most consistent change across all genes and both types of IFN. 
Fold change for each IFN compared to media alone was calculated. The ratio of fold change between IFN-α and 
IFN-γ is shown in Fig. 2A. For most genes, IFN-α fold change exceeded IFN-γ. For 7 of the 31 genes this was 
not found. Data for all time-points is shown for 3 genes that responded predominantly to IFN-α (Fig. 2B), and 
3 genes that responded to both IFN-α and IFN-γ (Fig. 2C). Both scores contained a number of genes whose 
expression was more responsive to IFN-α allowing the possibility that non-IFN pathways may contribute to the 
clustering of ISGs found between modules / factors.
We next tested whether a dose-response relationship to IFN-α was present for both scores. We stimulated 
PBMCs with doses of IFN-α from 0.01–10,000 U/mL. TaqMan gene expression were performed after 48 hours 
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(Fig. 2D). For gene expression, a dose dependent increase was observed between 1 and 1000 units of IFN-α. For 
gene expression on unsorted PBMCs, dose response was similar using IFN Score A or IFN Score B.
Clinical validation of IFN assays: diagnostic groups. We compared the performance of the ISG expres-
sion scores in distinguishing between patients with SLE (SLICC 2012 criteria, n = 114) or RA (ACR-EULAR 2011 
criteria, n = 32) versus HC (n = 49), controlling for age (Fig. 3), using ratio of expression and effect size. Full 
statistical table is shown in Table S6.
Comparing SLE with HC, we found the largest ratio and effect size for IFN Score A with ratio 9.35 (5.50, 
15.90). Although the ratio was smaller [3.90 (2.76, 5.52)] for IFN Score B, the effect size was very similar. When 
comparing SLE with RA, IFN Score A was elevated in SLE [ratio 6.11 (3.42, 10.89); large effect size]; IFN Score 
B did not differ greatly between SLE and RA [ratio 1.26 (0.87, 1.85)]. However, when comparing RA to HC, the 
reverse was true; IFN Score A did not differ [ratio 1.53 (0.75, 3.14), no detectable effect], whilst IFN Score B was 
elevated in RA patients [ratio 3.09 (1.93, 4.94), medium-large effect size]. To summarise: compared to HC, IFN 
Score A was only increased in SLE, while IFN Score B was increased in both SLE and RA.
Clinical validation of IFN scores: disease activity. In 114 SLE patients, imputation was required to 
address missing data in the BILAG scores (n = 2 patients), absolute lymphocyte count (n = 2), low complement 
(n = 9), ANA count (n = 14) and anti-dsDNA antibody titre (n = 20). IFN Score A was associated with ANA 
count (ratio per additional ANA reactivity (90% CI) 1.52 (1.23, 1.88), effect size = 0.13, P < 0.001; Fig. 4A) and 
lower lymphocyte count (ratio per 109/L 0.47 (0.30, 0.73) effect size = 0.10, P = 0.001; Fig. 4B), but not age, gen-
der, complement or anti-dsDNA antibody titre (all effect size < 0.01, P > 0.100). IFN Score B was not associated 
with ANA count (1.07 (0.95, 1.22), effect size = 0.01, P = 0.266), but the negative association with lymphocyte 
count remained substantive (0.66 (0.52, 0.83), effect size = 0.10, P = 0.001).
Gene
Reference from literature Module Rotated factor loading
Subsets PB 1.2 3.4 5.12 Factor 1:IFN Score-A Factor 2: IFN Score-B
ISG15 16,41,42 20,23,24,43 • 0.96*
IFI44 16,41,42,44 20,23,33,34,43,45 • 0.80*
IFI27 41,42,44 20,33,34 0.77*
CXCL10 41,42,44 6 • 0.71* (−0.41)
RSAD2 16,42 20,33,43 • 0.70*
IFIT1 41,42,44 43,45 • 0.67*
IFI44L 16,41,42 20,24,33,43 • 0.66*
CCL8 41 6 • 0.58*
XAF1 41,42 23,24,43,45 • 0.54*
IFI6 16,41,42 20,24,33 0.51 0.45
GBP1 41,42 6 • 0.46*
IRF7 16,41,42 43 • 0.46*
CEACAM1 42 6 • 0.45*
HERC5 16,41,42 20 • 0.43 0.59
EIF2AK2 16,41,42 45 • 0.42 0.64
MX1 16,41,42 20,23,24,43 • 0.40 0.56
LAMP3 41,42 43 • 0.40*
IFIH1 41,42 43 • 0.45*
PHF11 41 6 • 0.58*
SERPING1 41,42 24 • 0.60*
IFI16 41,42,44 6 • 0.64*
BST2 41,42,44 6,43 • 0.74*
SP100 42,44 6 • 0.74*
NT5C3B 6 • 0.80*
SOCS1 41,42 6 • 0.84*
TRIM38 41 6 • 0.87*
UNC93B1 41 6 • 0.88*
UBE2L6 16,42 43 • 0.89*
STAT1 16,41,44 6 • 0.94*
TAP1 16,44 43 • 0.98*
CASP1 41,42 6 • <0.40 <0.40
Table 1. Gene expression Interferon Scores A and B. Rotated factor loadings show the results of factor analysis. 
Values are substantive factor loadings (promax; pattern matrix exceeding 0.4) after rotation. *Indicates genes 
that were included in the factor scores. See supplementary material for further details of factor analysis.
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We used each IFN score as the outcome in multivariable linear regression models that included indicators for 
presence of activity (A, B or C) in the three most common BILAG domains (mucocutaneous, musculoskeletal and 
haematological, active in 46, 59 and 57 patients respectively) as independent variables, controlling for age and the 
blood markers of disease activity (excluding lymphocyte count since this is a component of the BILAG haemato-
logical score). This revealed a positive association between IFN Score A expression and mucocutaneous activity 
[ratio (90% CI) 1.71 (1.02, 2.86), effect size = 0.04, P = 0.042] and haematological activity [1.90 (1.11, 3.24), effect 
size = 0.04, P = 0.020], but not musculoskeletal activity [0.79 (0.46, 1.34), effect size = 0.00, P = 0.381]. Of the 
covariates, only ANA count was associated with IFN Score A expression [ratio per additional ANA 1.57 (1.26, 
1.95), effect size = 0.15, P < 0.001]. The same pattern was seen for IFN Score B [1.41 (1.08, 1.84), effect size = 0.05, 
P = 0.012; haematological 1.44 (1.09, 1.90), effect size = 0.05, P = 0.012; musculoskeletal 0.82 (0.63, 1.08), effect 
size = 0.01, P = 0.165]. This variation between organ systems may explain the lack of association with total BILAG 
(IFN Score A P = 0.906, Score-B P = 0.780). In Fig. 4C and D we present data to illustrate the relationship between 
skin and musculoskeletal disease activity and IFN scores. Numbers of patients with involvement of other organs 
were not sufficient for multivariate anlysis.
In the longitudinal casenote review, 59/60 the patients selected had complete data. We found a significant 
association between IFN cores and other clinical features of disease. Notably, a different relationship was found 
for each score and each disease feature. Objective flare occurred in 18/59 patients and was associated with signif-
icantly higher level of IFN Score A but not Score B. Median (IQR) Score A was 0.39 (1.08) for patients with flare 
compared to 0.024 (0.029) for patients without (p = 0.042). IFN Score B values were 0.34 (0.50) and 0.17 (0.30) 
respectively (p = 0.343). In contrast, internal organ involvement was present in 21/59 patients and was associated 
with a trend to higher levels of IFN Score A but significantly higher IFN Score B. Median (IQR) Score A was 0.04 
(1.15) for patients with internal organ involvement compared to 0.02 (0.40) for patients without (p = 0.124). IFN 
Score B values were 0.28 (0.64) and 0.12 (0.33) respectively (p = 0.037).
Bimodality. To explore bimodality, we created finite mixture models on IFN Score A and IFN Score B to 
determine whether they represented a mixture of 2 or more distributions. We also investigated individual genes 
for mixture distributions.
IFN Score A genes found to bimodally distributed were: IFI27, ISG15, CEACAM1, IFI44L, IFI44. The most 
strongly bimodal of these was IFI27; assigning patients to a ‘high’ or ‘low’ expression group based on this single 
gene instead of IFN Score A (Fig. 5A) increased the proportion with high expression from 45% to 46% and 
improved the mean probability of group membership from 0.89 to 0.92. IFN Score B genes found to be bimodally 
Figure 1. Comparison of expression of IFN Score A and IFN Score B between sorted immune cell subsets Age-
adjusted level of expression (2-dCT) of IFN Score A (Fig. 1A) and IFN Score B (Fig. 1B) in patients with SLE (red) 
and HC (white) for each cell subsets identified and sorted by flow cytometry of PBMCs. Figures 1C and D show 
ratio of expression (SLE:HC) for IFN Score A and Score-B respectively. A substantive increase in expression 
was observed for both scores in each subset. For both scores expression was greatest in monocytes. Dotted lines 
represent SLE = HC; details in Table S4.
www.nature.com/scientificreports/
5SCIENTIFIC REPORTS | (2018) 8:5793 | DOI:10.1038/s41598-018-24198-1
distributed were: SP100, NT5C3B, UNC93B1, TRIM38, STAT1, TAP1, BST2, UBE2L6, PHF11 & IFI16. The most 
strongly bimodal of these was SP100. Classifying patients using SP100 alone compared to IFN Score B (Fig. 5B) 
increased the proportion with high expression from 20% to 32% and improved mean probability of group mem-
bership from 0.97 to 0.99.
Mean IFN scores according to expression groups are plotted in Fig. 5C–F. Interestingly, high expression group 
of IFN Score-A was observed in most SLE patients (85/114) but not in the other groups (HC 8/49; UCTD 53/133; 
RA 5/32). In contrast, high expression of IFN Score B was seen in almost all SLE (112/114) and all RA patients 
(32) as well as many UCTD (57/133). Notably, 22/49 HC were also in the high group.
Overall, both IFN scores were found to be from a mixture of 2 distributions with a degree of overlap 
(Fig. 5G,H). The proportions of individuals classified as having high expression on IFI27 (IFN Score A) or SP100 
(IFN Score B), according to diagnosis, are presented in Fig. 5I,J.
Importantly, within each expression group, IFN scores still discriminated between diagnoses; Adjusting for 
age, in the high expression group SLE showed significantly higher IFN Score A than each other diagnosis. In the 
low expression group, IFN Score A differed between SLE and HC. For IFN Score B, in the high expression group, 
SLE showed higher expression than UCTD. Patients with UCTD in the low expression group had higher IFN 
Score B than HC.
In summary, although each IFN Score is bimodally distributed, analyzing the score as a continuous variable is 
more informative than by a simple high or low classification.
Discussion
In this study, we present a novel approach to measure IFN activity in autoimmunity. We developed and clinically 
validate a continuous two-score system, as well as its biological basis.
Figure 2. In vitro stimulation and expression of ISGs Expression of selected ISGs was measured following in 
vitro stimulation of B cells using either IFN-α or IFN-γ. Activated B cells were exposed to media alone or IFN-α 
or IFN-γ for between 1 and 96 hours before analysis of gene expression profile. (A) Shows log of ratio of increase 
in expression 6 hours after IFN-α vs. IFN-γ each compared to no stimulation. Results are mean of 3 healthy 
donors. Values greater than 0 indicate greater increase in expression with IFN-α than IFN-γ. Values below 
0 indicate greater increase in expression with IFN-γ than IFN-α. (B) Shows change in expression of 3 ISGs 
that predominantly respond to IFN-α. (C) Shows change in expression for 3 ISGs, which do not demonstrate 
selective response to IFN-α in B cells. (D) For dose-response, unsorted PBMCs were stimulated with increasing 
doses of IFN-α. RNA was extracted from unsorted PBMCs and used to measure expression of Interferon 
Score-A and Interferon Score-B.
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Previous microarray data demonstrated co-clustering ISGs in modules to decipher multiple IFN signatures 
within SLE patients. These modules revealed different strength of association with disease activity. In a previous 
publication expression of these modules in patients receiving exogenous IFN-α and IFN-β for hepatitis C and mul-
tiple sclerosis respectively suggested that module M1.2 was responsive only to IFN-α and modules M3.4 and M5.12 
were also responsive to IFN-β6. These data may have been affected by the disease under study, but interferome data 
also indicated that modules M1.2 and M3.4 were induced by IFN-β more than IFN-α and both M3.4 and M5.12 
were also responsive to IFN-II (IFN-γ)6. Our factor analysis segregates ISGs in a similar fashion to this work: Score 
B mostly included genes found in M3.4 and M5.12. However, although there was a trend to a less selective IFN-α 
response in Score B our in vitro data did not show such a clear relationship between ISG subsets and subtypes of IFN.
Another hypothetical explanation for these ISG sets is that they reflect changes in numbers of circulating 
immune cells, which characteristically occur with disease activity in autoimmunity or immunosuppressive ther-
apy, such as lymphopenia16. Our results did not support this explanation; we found both scores to be upregulated 
in SLE in all cell types. We cannot exclude the possibility that other non-IFN immune mediators may influence 
the clustering of ISGs. Further studies would be needed to answer this. Nevertheless, we have shown that separat-
ing ISG expression into two scores is clinically relevant. Most notably, many papers have described IFN activity in 
RA3,4, but we show that this is qualitatively different to SLE, with elevation of IFN Score B only.
Our factor analysis also expanded on previous work by measuring IFN activity as a continuous score instead 
of the bimodal classification as “IFN-high” and “IFN-low” commonly reported in other studies. Previous studies 
defined variable IFN-scores using as bimodal (High/low) [5, 6] either by 95% centile of Healthy donors as cutoff 
or >50% of the patients overlapping with HC as IFN-Low. This classification has led to inconsistent results in 
prediction of response to IFN-blocking therapy [6–8]. We found that both scores are indeed bimodal; there are 
two overlapping normal distributions underlying the distribution seen in patients (Fig. 5A and B). However, 
these distributions are not equivalent to normal and abnormal; many healthy individuals were in the high group. 
Further, there was variation within the high and low groups according to diagnosis. It therefore appears more 
appropriate to use a continuous measure of IFN activity in research or clinical practice.
Other ISG-based assays showed association with disease activity in cross-sectional studies23,24,30, particularly 
with skin lupus, but not with other common manifestations such as arthritis and haematological disease15. However, 
these were inconsistent with other studies failing to demonstrate any association11,13. Most did not adjust for activity 
in multiple organs and confounders. This is important because of the clinical and immunological heterogeneity 
of SLE. Patients with active or inactive disease in one organ system may have simultaneous activity in other organ 
systems independently. We controlled for this variability with multivariate analysis and by comparing patients with 
single-organ disease only. This revealed a variable relationship between IFN activity and different manifestations of 
SLE, with notably increased IFN activity in skin, but not musculoskeletal, disease activity. This explains the poor or 
inconsistent relationship between IFN and global disease activity reported in other studies. Both of our IFN scores 
showed associations with serology and features of disease activity (BILAG domains) in adjusted models, albeit with 
some differences in strength, indicating their advantage for stratifying disease. Further, we found a difference in 
interferon profile between patients who experienced flares and patients with internal organ involvement, which 
suggests that these two scores will be of greater value in longitudinal studies, which we are currently conducting.
In conclusion, we describe novel IFN scores as a new method to analyse the IFN-I pathway in autoimmunity. 
These scores should be used to measure IFN status in stratification research. Our future work will further assess 
the clinical usefulness of IFN-I response assays, including prediction of clinical progression in at risk individuals, 
flares, and response to conventional and B cell-targeted therapy.
Figure 3. Comparison of gene expression IFN scores against diagnosis. Age-adjusted differences between 
patients with SLE (red) and patients with active RA (DAS28 > 3.2; blue) or HC (white) in (A) IFN Scores. Effect 
sizes (partial eta squared) indicate which of the variables differed to the greatest extent between the different 
groups. We considered effect size 0.01 to be small, 0.06 to be medium and 0.14 to be large40.
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Figure 4. Association of IFN scores with other clinical immunology parameters Associations between each 
IFN score with (A) the number of ANA present, and (B) absolute lymphocyte count (observed data only). 
In panel A, ‘ + ’ = mean, ‘−‘ = mean ± 1 SD. ANA count refers to number of anti-extractable nuclear antigen 
(ENA) antibodies; including: Anti- Sm, RNP, Ro (SS-A), La (SS-B), Jo-1, Scl-70. (C) Shows Score A for patients 
with no disease activity (n = 66), active disease in the mucocutaneous system only (BILAG A or B, n = 24), 
active disease in the musculoskeletal system only (BILAG A or B, n = 26), or activity in both systems at the same 
time (n = 14). (D) Shows IFN Score B for the same patient groups.
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Methods
Patients and healthy donor participants. All individuals gave informed written consent and research 
was carried out in compliance with the Helsinki Declaration. The patients’ blood samples used for this study 
were collected under ethical approval, REC 10/H1306/88, National Research Ethics Committee Yorkshire and 
Humber–Leeds East, and healthy control participants’ peripheral blood was collected under the study number 04/
Q1206/107. All experiments were performed in accordance with relevant guidelines and regulations.
SLE patients met ACR/SLICC 2012 criteria. All RA patients met ACR/EULAR 2010 criteria (ACPA-positive 
but ANA-negative)31. Disease activity was assessed using BILAG-200432. Undifferentiated connective tissue dis-
ease (UCTD) patients were individuals with positive ANA but did not meet criteria for CTD. Healthy controls 
(HC) had no autoimmune diseases or other infectious or inflammatory disease at the time of sampling. Absolute 
lymphocyte count was obtained from a routine diagnostic laboratory and used to calculate absolute counts for 
flow cytometry subsets. Number of reactivates against dsDNA, Ro52, Ro60, La, Sm, RNP, Sm/RNP and chromatin 
was measured using Bioplex 2200 and expressed as “ANA count”.
Flow cytometry and cell sorting. Peripheral blood mononuclear cells (PBMCs) were separated using 
density gradient method (LymphoprepTM, Alere Technologies, Norway) from EDTA-anticoagulated blood. Flow 
cytometry was performed using a Becton Dickinson (BD) LSRII flow cytometer and analysis using BD FACSDiva 
software. A six-way FACS was performed on a BD Influx™ to pure lymphocyte subsets. Purity of sorted pop-
ulations was confirmed before RNA extraction using flow cytometry (>98% purity for each subset) as well as 
expression of lineage marker genes. Antibodies are shown in Table S1.
Figure 5. Bimodality of IFN score genes. Analysis of bimodality was performed using samples from all 
SLE, RA, UCTD and HC individuals (n = 328). A, B, G, H show histograms of reflected dCt values overlaid 
with estimated density functions for 2 separate normal distributions (solid line = ‘high’ expression; dashed 
line = ‘low’ expression) identified using finite mixture modelling of (A) IFI27; (B) SP100; (G) Score A; (H) 
Score B. In common with previous studies we observed a bimodal distribution of IFN activity as measured 
by each IFN score (G and H). We used IFI27 (A) and SP100 (B) as the most bimodal gene within Score A 
and B respectively to classify patients into low and high expression groups. (C–F) Show the level of IFN 
Score (reflected dCT) for each group of individuals within the high and low expression groups. These results 
show that SLE patients in the high expression group had a significantly higher level of Score A than RA and 
UCTD patients or HC individuals in the high expression group (*P < 0.1). (I) and (J) show the proportions of 
individuals classified within the high expression group for each diagnosis; notably 16.3% and 44.9% of HC were 
classified within the high group.
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Gene probe selection and gene expression. 10 genes were selected from each IFN-annotated module (M1.2, 
M3.4, M5.12)15, with additional common ISGs (IFI27, IFI6)20,24,33,34. The selected genes were validated by meta-analysis 
of multiple GEO data biosets35 comparing PBMCs from SLE versus HC on Nextbio web engine36. Peptidylprolyl 
isomerase A (cyclophilin A) (PPIA) was used as a reference gene (confirmed not to respond to IFN-I37).
Gene expression studies. Total RNA purification kit (Norgen Biotek, Canada) was used to extract 
RNA from PBMCs and sorted cell subsets. For cDNA synthesis from total RNA acquired, Fluidigm® Reverse 
Transcription Master Mix buffer was used according to manufacturer’s instructions including a mixture of ran-
dom primers and oligo dT for priming. TaqMan assays (Applied Biosystems, Invitrogen) were used to perform 
the qPCR (Table S2). TaqMan Gene Expression Assays were performed using the BioMark™ HD System and 
appropriate cycling protocols for the 96.96 chip. Expression of lineage markers and ISGs was analysed by relative 
quantitative reverse transcription–polymerase chain reaction (qRT–PCR) using TaqMan reagents from Applied 
Biosystems. Gene expression data were normalised to PPIA and calculated using ΔCt method for analysis, then 
transformed using 2−Δ (Δ)Ct.
Multiple Imputation. Predictive mean matching (using 10 nearest neighbours) was used for continuous 
variables, logistic regression for binary variables. Models included age and IFN scores. We combined results from 
analyses performed in 20 imputed datasets according to Rubin’s rules. Effect sizes from each imputed dataset were 
Fisher z transformed, averaged across imputations, then back-transformed.
Factor Analysis. Factor analysis (FA) was used to determine whether the gene expression values of multiple 
genes were driven by a smaller number of unobserved (latent) continuous variables. FA included expression levels 
for ISGs measured in the PMBCs from SLE, UCTD, RA and HC.
Prior to factor analysis (FA), undetected ∆Ct values were singly imputed using the R package nondetects38. 
The Kaiser-Meyer-Olkin measure was used to verify the sampling adequacy of the analysis39. Principal factor 
extraction, without rotation, was used to identify the optimum number of factors, which was initially determined 
according to a parallel analysis (Monte Carlo simulation using 1000 replications). This indicated the maximum 
number of factors present, but if a smaller number of factors were required to explain 80% of the variance, and 
resulted in lower levels of cross-loading (genes loaded by 2 or more factors at >0.4), a simpler structure was 
selected. Having identified the number of factors present, oblique (promax; kappa = 4) rotation was used to 
obtain the final factor solution. To calculate factor scores, within each patient median gene expression was cal-
culated for genes loaded at ≥0.4 by each factor, provided they did not cross-load onto more than one factor. The 
advantage of this approach was that it reflected the variability of the data, and respected the within-patient ordinal 
scaling of delta Ct values where some genes were below the detection threshold, but yielded factor scores in units 
(delta Ct) that were easily interpreted in subsequent analyses.
Factor scores were calculated as the median expression (dCt scale) of genes loaded by each factor at ≥0.4, 
provided they were not loaded by more than one factor.
Statistical Analysis. To compare gene expression levels between sorted cell subtypes, substantive descriptive 
differences were considered evidence of heterogeneity, given the sample size. We considered P < 0.1 indicative of 
potential differences, and P < 0.2 indicative of potential interactions.
Multilevel linear regression modeling (random intercepts, fixed slopes, unstructured covariance) was used to 
assess whether a) expression levels differed between sorted cell subtypes in SLE patients and b) the differences 
between SLE patients and HC differed according to subset type, controlling for age. Cell subsets were considered 
nested at the patient level. Monocytes were the reference against which other cell types were compared.
Analysis of covariance, controlling for age, compared patients with SLE to those with RA and to HC. Post-hoc 
pairwise tests were corrected for multiplicity (Tukey HSD method). Effect sizes (partial omega squared) were 
calculated; we considered effect sizes to be small (0.01), medium (0.06) or large (0.14) as described by Cohen40.
Multiple imputation by chained equations was used to impute missing disease activity measures within SLE 
patients (for details see supplementary material).
IFN scores were modelled as a function of ANA count, low complement, lymphocyte count and anti-dsDNA 
titre using linear regression. Linear regression was then used to relate IFN scores to presence of individual BILAG 
organ activity (A, B or C) controlling for age and each of the blood measures of disease activity described above. 
Quantile (median) regression was used to relate total BILAG and SLEDAI scores to IFN scores, controlling for 
the same covariates.
Finite mixture modelling (FMM) was used to explore whether IFN-Scores-A and -B each represented a 
mixture of 2 or more distributions. On the dCt scale, normal (Gaussian) distributions were assumed. Akaike’s 
Information Criterion (AIC) and Bayesian Information Criterion (BIC) were used to compare the fit of models 
with 1, 2 or more components. We restricted the analysis of distribution of individual gene expression to patients 
in whom expression could be measured.
We performed an analysis of available longitudinal data in our patients as a pilot for future formal longitudinal 
studies. We selected 60 patients across a spectrum of levels of IFN Score A and Score B and reviewed casenotes 
for objective flare and involvement of internal organs. Objective flare was defined by documentation of flare 
accompanied by clinical signs such as joint swelling, or confirmatory investigations such as renal biopsy, as well 
as new or increased treatment within 3 months of biomarker testing. Internal organ involvement was defined by 
confirmed and treated lupus activity in cardiorespiratory, renal and CNS systems at any prior date. 2−dCT values 
were compared using Mann Whitney U tests.
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